Redeye adjusts its estimates and valuation for Fluoguide's directed share issue.
* Net sales SEK 174m, -3% vs ABGSCe * EBITA SEK 24m, -18% vs ABGSCe * Cole & Son platform to be upgr...
Alisa Bank intends to sell the majority of its consumer loan portfolio.
Redeye provides a research update following IRLAB's recent Q3 report.
NoHo Partners reported Q3 EBIT of EUR 7.6m from continuing operations (down 13% y/y), 12% below Vara...
* 35% organic sales growth in Q3 (ABGSCe +38%) Adj.
Aspo will list or divest its ESL Shipping segment in 2026.
Redeye comments on Hansa Biopharma's Q3 report. Product sales declined sequentially in Europe.
Redeye was surprised by the news that CEO Johan Rask is leaving the company.
Redeye briefly comments on Initiator Pharma’s announcement that its Clinical Trial Application (CTA)...
* A Nordic distributor of PPE, tools etc. returning to org.
Administer is set to report Q3 results on November 5.
Marimekko’s Q3 brought no major surprises, with both net sales and profitability roughly in line wit...
Redeye updates on Embracer ahead of Q2-results (due 13 November) where we expect another quarter wit...
Redeye updates its estimates and fair value range following CTEK’s Q3 report published on Thursday l...
Redeye updates its estimates and valuation following Tradedoubler’s Q3 2025 report.
Redeye updates its forecast and valuation following Modelon’s Q3 2025 report, which was broadly in l...
NoHo Partners will publish its Q3 2025 results on 4 October, at around 8:00 EET.
Redeye comments on Iconovo’s appointment of a new CEO.
Finnair’s biggest challenges this year may now be in the past, yet it still needs to achieve signifi...
